Schatzberg, Alan F.
Mathew, Sanjay J. http://orcid.org/0000-0002-2715-6641
Article History
Received: 10 April 2023
Revised: 22 June 2023
Accepted: 27 June 2023
First Online: 17 July 2023
Competing interests
: AFS has served as a consultant to Alto Neuroscience, ANeurotech, Compass, Magnus, NeuraWell, Parexel, Sage and Signant. He holds equity in Alto Neuroscience, Corcept, Delpor, Madrigal, Magnus, Seattle Genetics, Titan and Xhale. SJM has served as a consultant to Almatica Pharma, Axsome Therapeutics, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Eleusis, EMA Wellness, Engrail Therapeutics, Janssen, Levo Therapeutics, Perception Neurosciences, Praxis Precision Medicines, Neumora, Neurocrine, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion, and XW Pharma. He has received research support from Boehringer-Ingelheim, Merck, Neurocrine, and Sage Therapeutics.